MUK
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bayes Theorem
Clinical Trials, Phase II as Topic
Cohort Studies
Dexamethasone
/ therapeutic use
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Plasma Cell
/ diagnosis
London
Multicenter Studies as Topic
Multiple Myeloma
/ diagnosis
Quality of Life
Transplantation, Autologous
clinical trials
myeloma
statistics & research methods
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
24 03 2021
24 03 2021
Historique:
entrez:
25
3
2021
pubmed:
26
3
2021
medline:
20
5
2021
Statut:
epublish
Résumé
Multiple myeloma (MM) is a plasma cell tumour with over 5800 new cases each year in the UK. The introduction of biological therapies has improved outcomes for the majority of patients with MM, but in approximately 20% of patients the tumour is characterised by genetic changes which confer a significantly poorer prognosis, generally termed high-risk (HR) MM. It is important to diagnose these genetic changes early and identify more effective first-line treatment options for these patients. The Myeloma UK Ethics approval London South East Research Ethics Committee (Ref: 17/LO/0022, 17/LO/0023). Results of studies will be submitted for publication in a peer-reviewed journal. ISRCTN16847817, May 2017; Pre-results.
Identifiants
pubmed: 33762245
pii: bmjopen-2020-046225
doi: 10.1136/bmjopen-2020-046225
pmc: PMC7993167
doi:
Substances chimiques
Dexamethasone
7S5I7G3JQL
Banques de données
ISRCTN
['ISRCTN16847817']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e046225Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: SH, DS, LF, SR, AH, KW and SB declare they have no competing interests. MK has served as a consultant and received honoraria from Celgene, Takeda, Amgen, Chugai, BMS, AbbVie and Janssen, and has received research funding from Celgene. GP served as a consultant and received honoraria from Janssen Oncology, Celgene, Amgen, Takeda, Gilead Sciences and Binding Site. MJ has served as a consultant and received honoraria from Celgene, Janssen, Takeda, Amgen, AbbVie and Novartis.
Références
J Clin Oncol. 2013 Jul 10;31(20):2540-7
pubmed: 23733781
Lancet Oncol. 2016 Jan;17(1):27-38
pubmed: 26671818
Radiology. 2019 Apr;291(1):5-13
pubmed: 30806604
Clin Cancer Res. 2011 Dec 1;17(23):7240-7
pubmed: 21986844
J Clin Oncol. 1996 Jan;14(1):296-303
pubmed: 8558211
Blood. 2006 Jan 1;107(1):397-403
pubmed: 16144800
Blood. 2007 Apr 15;109(8):3177-88
pubmed: 17185464
J Clin Oncol. 2015 Oct 20;33(30):3459-66
pubmed: 26282661
Blood. 2011 Aug 4;118(5):1231-8
pubmed: 21652683
Lancet Haematol. 2020 Jun;7(6):e456-e468
pubmed: 32359506
Cancer Imaging. 2020 Jul 14;20(1):48
pubmed: 32665028
N Engl J Med. 2012 May 10;366(19):1782-91
pubmed: 22571202
Clin Trials. 2017 Aug;14(4):349-356
pubmed: 28532202
Leukemia. 2012 Nov;26(11):2406-13
pubmed: 22722715
Hematology Am Soc Hematol Educ Program. 2010;2010:489-93
pubmed: 21239841
J Clin Oncol. 2020 Sep 20;38(27):3107-3118
pubmed: 32687451
Br J Haematol. 2006 Oct;135(2):158-64
pubmed: 16939489
Lancet Oncol. 2019 Jan;20(1):57-73
pubmed: 30559051
J Clin Oncol. 2012 Jun 1;30(16):1949-52
pubmed: 22547600
Br J Haematol. 2007 Jul;138(2):176-85
pubmed: 17593024
Blood. 2012 Jan 26;119(4):940-8
pubmed: 22160383
Leukemia. 2012 Feb;26(2):349-55
pubmed: 21836613
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
Blood. 2012 Jan 5;119(1):7-15
pubmed: 22021371
Leukemia. 2014 Feb;28(2):269-77
pubmed: 23974982
Blood. 2010 Jan 7;115(1):32-7
pubmed: 19884643
Leukemia. 2020 Nov;34(11):3091-3096
pubmed: 32157174
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Stat Med. 1998 Jul 30;17(14):1563-80
pubmed: 9699230
Blood. 2013 Feb 7;121(6):884-92
pubmed: 23165477
Leukemia. 2013 Mar;27(3):711-7
pubmed: 23032723
Leukemia. 2008 Feb;22(2):459-61
pubmed: 17805328
Blood. 2016 Oct 6;128(14):1821-1828
pubmed: 27531679
J Clin Oncol. 2019 Jul 1;37(19):1657-1665
pubmed: 31091136
Haematologica. 2016 Apr;101(4):e142-4
pubmed: 26819048
J Clin Oncol. 2009 Dec 1;27(34):5720-6
pubmed: 19826130
J Clin Oncol. 2014 Sep 1;32(25):2712-7
pubmed: 25024076
Leukemia. 2013 Aug;27(8):1754-7
pubmed: 23318961
Lancet. 2010 Dec 11;376(9757):1989-99
pubmed: 21131037
Blood. 2007 Mar 15;109(6):2276-84
pubmed: 17105813
N Engl J Med. 2012 May 10;366(19):1770-81
pubmed: 22571201
Leukemia. 2018 Jan;32(1):102-110
pubmed: 28584253
Blood. 2021 Jan 7;137(1):49-60
pubmed: 32693406
Blood. 2011 Oct 20;118(16):4359-62
pubmed: 21860025
Stat Med. 1995 Feb 28;14(4):357-79
pubmed: 7746977
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Br J Haematol. 2009 Nov;147(3):347-51
pubmed: 19702643
Leuk Lymphoma. 2013 Sep;54(9):1975-81
pubmed: 23270579
J Clin Oncol. 2015 Nov 20;33(33):3911-20
pubmed: 26282654
Clin Cancer Res. 2010 Mar 15;16(6):1856-64
pubmed: 20215539
N Engl J Med. 2015 Jan 8;372(2):142-52
pubmed: 25482145
J Clin Oncol. 2007 Jun 10;25(17):2434-41
pubmed: 17485707
Blood. 2012 May 10;119(19):4375-82
pubmed: 22422823
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
J Clin Oncol. 2010 Oct 20;28(30):4621-9
pubmed: 20823406
Future Oncol. 2015;11(15):2121-36
pubmed: 26125319
J Clin Oncol. 2008 Oct 10;26(29):4798-805
pubmed: 18591550
Br J Haematol. 2015 Oct;171(1):29-37
pubmed: 26013304